We tried to find novel therapeutic possibilities using SB525334, a potent and selective inhibitor of the TGF-β receptor I (ALK5), as an anti-EMT drug in HK2 cells, in addition to α-gal A ERT for FD patients. Here, TGFBR1 is linked to Fabry disease.